FATE THERAPEUTICS INC Share-based Payment Arrangement, Noncash Expense
FATE THERAPEUTICS INC (FATE) reported Share-based Payment Arrangement, Noncash Expense of $2.40 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2016-03-03
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for the quarter ending 2015-12-31 was $480.00K, a 21.57% decline year-over-year.
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for the quarter ending 2015-09-30 was $574.00K, a 8.92% increase year-over-year.
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for the quarter ending 2015-06-30 was $738.00K, a 74.06% increase year-over-year.
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for the quarter ending 2015-03-31 was $608.00K, a 30.20% decline year-over-year.
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for fiscal 2015 was $2.40M, a 1.40% decline from fiscal 2014.
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for fiscal 2014 was $2.43M, a 56.63% increase from fiscal 2013.
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for fiscal 2013 was $1.55M, a 902.58% increase from fiscal 2012.
- FATE THERAPEUTICS INC share-based payment arrangement, noncash expense for fiscal 2012 was $155.00K, a 9.88% decline from fiscal 2011.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 77 month | Share-based Payment Arrangement, Noncash Expense 80 month | Share-based Payment Arrangement, Noncash Expense 83 month |
|---|---|---|---|---|---|---|---|
| 2015-12-31 | $480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $1.05M derived: sum of 2 quarters · filed 2016-03-03 | $1.79M derived: sum of 3 quarters · filed 2016-03-03 | $2.40M 10-K · filed 2016-03-03 | |||
| 2015-09-30 | $574.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $1.31M derived: sum of 2 quarters · filed 2015-11-03 | $1.92M 10-Q · filed 2015-11-03 | $2.53M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2015-06-30 | $738.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.35M 10-Q · filed 2015-08-05 | $1.96M derived: sum of 3 quarters · filed 2016-03-03 | $2.48M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2015-03-31 | $608.00K 10-Q · filed 2015-05-07 | $1.22M derived: sum of 2 quarters · filed 2016-03-03 | $1.75M derived: sum of 3 quarters · filed 2016-03-03 | $2.17M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $1.14M derived: sum of 2 quarters · filed 2016-03-03 | $1.56M derived: sum of 3 quarters · filed 2016-03-03 | $2.43M 10-K · filed 2016-03-03 | |||
| 2014-09-30 | $527.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $951.00K derived: sum of 2 quarters · filed 2015-11-03 | $1.82M 10-Q · filed 2015-11-03 | $2.21M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | $424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.29M 10-Q · filed 2015-08-05 | $1.68M derived: sum of 3 quarters · filed 2016-03-03 | $2.66M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | $871.00K 10-Q · filed 2015-05-07 | $1.26M derived: sum of 2 quarters · filed 2016-03-03 | $2.24M derived: sum of 3 quarters · filed 2016-03-03 | $2.35M derived: sum of 4 quarters · filed 2016-03-03 | $3.19M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $385.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $1.37M derived: sum of 2 quarters · filed 2016-03-03 | $1.48M derived: sum of 3 quarters · filed 2016-03-03 | $1.55M 10-K · filed 2016-03-03 | $2.32M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $982.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $1.09M derived: sum of 2 quarters · filed 2014-11-12 | $1.17M 10-Q · filed 2014-11-12 | $1.22M derived: sum of 4 quarters · filed 2015-03-12 | $1.94M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $187.00K 10-Q · filed 2014-08-12 | $236.00K derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $75.00K 10-Q · filed 2014-05-13 | $124.00K derived: sum of 2 quarters · filed 2015-03-12 | |||||
| 2012-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $155.00K 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | $106.00K 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | $172.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |